Will the 25th Amendment be used during Trump's Presidency?

**Stage 1 — Blind analysis (ignore market prices):**

The baseline institutional facts strongly favor a low probability that the 25th Amendment will be used to remove a sitting President against his will. Section 4 requires the vice president plus a majority of Cabinet secretaries to declare the President unable to discharge the powers and duties of office. If the President contests, a two-thirds vote in both Houses of Congress is required to make that declaration permanent. Historically, the 25th Amendment has never been used to forcibly remove a President; past usage has been limited to voluntary, temporary transfers of power (Section 3) for routine medical procedures. Those institutional frictions — need for VP + majority of Cabinet, and Congress as the ultimate arbiter if contested — make an involuntary removal extremely difficult absent an obvious catastrophic incapacity or explicit coordination among senior officials.

Medical risk factors (age 80 in 2026) raise the chance of medical events relative to younger Presidents. An 80-year-old male faces materially higher baseline risks of acute events (stroke, heart attack, major surgery) over a 3–4 year term than a younger peer, which increases the chance of some transfer of power. However, the probability that any such medical event would meet the specific political and legal threshold for a Section 4 invocation — enough that the VP and a majority of Cabinet would coordinate and be willing to withstand enormous political blowback — is small. The much likelier use of the Amendment would be a voluntary Section 3 transfer for planned surgery or a temporary incapacity when the President and his medical team cooperate with the vice president to effect a short transfer of power. Whether Trump would voluntarily invoke Section 3 depends on his willingness to cede power even temporarily; he has repeatedly asserted robust health and public competence, which lowers the chance of voluntary transfers but does not eliminate them.

Weighing these elements, I decompose the event into two pathways and rough probability components: (A) a voluntary/medical transfer under Section 3 for planned procedures or short-term incapacity — modestly likely given age and standard medical practice, call this the primary contributor to the overall chance; (B) an involuntary Section 4 removal (VP + Cabinet) prompted by cognitive decline, acute incapacitation with political consequences, or a political revolt — very unlikely. Combining these, my independent estimate for any invocation (Section 3 or 4, temporary or contested) during the remainder of the term is 18%. That reflects a non-negligible chance of a temporary Section 3 use (perhaps 13–16%) plus a small tail risk for a Section 4 process (2–5%).

**Stage 2 — Market calibration (look at market prices now):**

The market is pricing Yes at ~27%, noticeably higher than my independent 18%. Several behavioral and informational explanations could account for that gap:

- *Attention and salience bias.* Intense media attention to Trump's age and cognitive-health chatter inflates perceived likelihood among retail bettors. Markets often over-weight current news cycles; sustained coverage of age/health raises short-term demand for Yes contracts even without new institutional signals. - *Ambiguity about question scope.* Some traders may assume the question counts any use (including trivial, voluntary Section 3 transfers for brief procedures). If traders believe Section 3 for routine medical procedures is likely, they may push the price higher than an analyst who discounts Trump's willingness to use Section 3. - *Asymmetric risk appetite / hedging.* Political insiders or opposition-aligned bettors may pay up for Yes as a hedge or because they place extra weight on tail scenarios (sudden incapacitation, Cabinet rebellion). That can push prices above a careful actuarial estimate. - *Information asymmetry.* There may be bettors trading on private information (rumors of health troubles or Cabinet unrest) that is not visible in public reporting. This possibility deserves respect, but absent corroboration, it should be treated cautiously.

Given those dynamics, I view the market as somewhat overpriced relative to the institutional and medical baseline. If you accept that "use" includes routine, voluntary, temporary Section 3 transfers (e.g., for anesthesia), then the market's 27% is more plausible — but only if you also believe Trump will follow precedent for medical transfers. If, instead, you think Trump is unlikely to voluntarily cede power and that a Cabinet-led Section 4 is extremely unlikely, then 27% is too high.

My judgment: the market is biased upward by salience and heterogenous definitions of "use." Absent a clear, credible report of serious health trouble or a fracture between the President and his VP/Cabinet, the most likely path to invocation is a limited, voluntary Section 3 transfer for a medical procedure; the chance of a contested Section 4 removal remains very small.